{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:59:25Z","timestamp":1790013565394,"version":"4.0.1"},"reference-count":39,"publisher":"e-Century Publishing Corporation","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/hvrh6856","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T04:18:11Z","timestamp":1748578691000},"page":"2193-2207","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and toxicity of PD-1 inhibitor combined with induction chemotherapy for locally advanced laryngeal and hypopharyngeal cancers"],"prefix":"10.62347","volume":"15","author":[{"given":"Tingting","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"243","DOI":"10.14639\/0392-100X-N1992","article-title":"Voice outcomes in patients with advanced laryngeal and hypopharyngeal cancer treated with chemo-radiotherapy","volume":"42","author":"&#xC1","year":"2022","unstructured":"Álvarez-Marcos C, Vicente-Benito A, Gayol-Fernández Á, Pedregal-Mallo D, Sirgo-Rodríguez P, Santamarina-Rabanal L, Llorente JL, López F and Rodrigo JP. Voice outcomes in patients with advanced laryngeal and hypopharyngeal cancer treated with chemo-radiotherapy. Acta Otorhinolaryngol Ital 2022; 42: 243-249.","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3390\/jcm12031237","article-title":"Current therapeutic strategies for patients with hypopharyngeal carcinoma: oncologic and functional outcomes","volume":"12","author":"Bozec","year":"2023","unstructured":"Bozec A, Poissonnet G, Dassonville O and Culié D. Current therapeutic strategies for patients with hypopharyngeal carcinoma: oncologic and functional outcomes. J Clin Med 2023; 12: 1237.","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12070-020-01806-z","article-title":"Role of total laryngopharyngoesophagectomy with gastric pull up in the management of locally advanced hypopharyngeal cancers","volume":"74","author":"Devaraja","year":"2022","unstructured":"Devaraja K, Pujary K, Ramaswamy B, Nayak DR, Shenoy KR and Rao P. Role of total laryngopharyngoesophagectomy with gastric pull up in the management of locally advanced hypopharyngeal cancers. Indian J Otolaryngol Head Neck Surg 2022; 74: 127-135.","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.hoc.2021.05.005","article-title":"Cancer of the larynx and hypopharynx","volume":"35","author":"Echanique","year":"2021","unstructured":"Echanique KA, Evans LK, Han AY, Chhetri DK and St John MA. Cancer of the larynx and hypopharynx. Hematol Oncol Clin North Am 2021; 35: 933-947.","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1007\/s00262-023-03550-z","article-title":"PD-1 Inhibitors combined with paclitaxel (Albumin-bound) and cisplatin for larynx preservation in locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: a retrospective study","volume":"72","author":"Fang","year":"2023","unstructured":"Fang Q, Xu P, Cao F, Wu D and Liu X. PD-1 Inhibitors combined with paclitaxel (Albumin-bound) and cisplatin for larynx preservation in locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: a retrospective study. Cancer Immunol Immunother 2023; 72: 4161-4168.","journal-title":"Cancer Immunol Immunother"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical hodgkin lymphoma","volume":"39","author":"AJ","year":"2021","unstructured":"Moskowitz AJ, Shah G, Schöder H, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Ryu S, Sohail S, Santarosa A, Galasso N, Neuman R, Liotta B, Blouin W, Kumar A, Lahoud O, Batlevi CL, Hamlin P, Straus DJ, Rodriguez-Rivera I, Owens C, Caron P, Intlekofer AM, Hamilton A, Horwitz SM, Falchi L, Joffe E, Johnson W, Lee C, Palomba ML, Noy A, Matasar MJ, Pongas G, Salles G, Vardhana S, Sanin BW, von Keudell G, Yahalom J, Dogan A, Zelenetz AD and Moskowitz CH. Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical hodgkin lymphoma. J Clin Oncol 2021; 39: 3109-3117.","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"100296","DOI":"10.1016\/j.ctarc.2020.100296","article-title":"Role of immunotherapy in bladder cancer","volume":"26","author":"Rhea","year":"2021","unstructured":"Rhea LP, Mendez-Marti S, Kim D and Aragon-Ching JB. Role of immunotherapy in bladder cancer. Cancer Treat Res Commun 2021; 26: 100296.","journal-title":"Cancer Treat Res Commun"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jamaoncol.2023.5258","article-title":"Atezolizumab and platinum plus pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer: a phase 3 randomized clinical trial","volume":"10","author":"Shiraishi","year":"2024","unstructured":"Shiraishi Y, Kishimoto J, Sugawara S, Mizutani H, Daga H, Azuma K, Matsumoto H, Hataji O, Nishino K, Mori M, Shukuya T, Saito H, Tachihara M, Hayashi H, Tsuya A, Wakuda K, Yanagitani N, Sakamoto T, Miura S, Hata A, Okada M, Kozuki T, Sato Y, Harada T, Takayama K, Yamamoto N, Nakagawa K and Okamoto I. Atezolizumab and platinum plus pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol 2024; 10: 315-324.","journal-title":"JAMA Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.3390\/cancers13071735","article-title":"Matched-pair analysis of survival in the patients with advanced laryngeal and hypopharyngeal squamous cell carcinoma treated with induction chemotherapy plus chemo-radiation or total laryngectomy","volume":"13","author":"Garc&#xED","year":"2021","unstructured":"García-Cabo P, López F, Sánchez-Canteli M, Fernández-Vañes L, Álvarez-Marcos C, Llorente JL, Rúa MÁ, Blay P and Rodrigo JP. Matched-pair analysis of survival in the patients with advanced laryngeal and hypopharyngeal squamous cell carcinoma treated with induction chemotherapy plus chemo-radiation or total laryngectomy. Cancers (Basel) 2021; 13: 1735.","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","unstructured":"Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M and Janjigian YY. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 2022; 603: 942-948.","journal-title":"Nature"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1341584","DOI":"10.3389\/fimmu.2023.1341584","article-title":"Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study)","volume":"14","author":"Wang","year":"2023","unstructured":"Wang Y, Deng L, Wang J, Zhang T, Wang W, Wang X, Liu W, Wu Y, Lv J, Feng Q, Zhou Z, Wang J, Wang L, Wang Z and Bi N. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study). Front Immunol 2023; 14: 1341584.","journal-title":"Front Immunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.eururo.2023.05.011","article-title":"Checkpoint inhibitors in urothelial carcinoma-future directions and biomarker selection","volume":"84","author":"Meeks","year":"2023","unstructured":"Meeks JJ, Black PC, Galsky M, Grivas P, Hahn NM, Hussain SA, Milowsky MI, Steinberg GD, Svatek RS and Rosenberg JE. Checkpoint inhibitors in urothelial carcinoma-future directions and biomarker selection. Eur Urol 2023; 84: 473-483.","journal-title":"Eur Urol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"403","author":"Liu","year":"2024","unstructured":"Liu X, Zhang Y, Yang KY, Zhang N, Jin F, Zou GR, Zhu XD, Xie FY, Liang XY, Li WF, He ZY, Chen NY, Hu WH, Wu HJ, Shi M, Zhou GQ, Mao YP, Guo R, Sun R, Huang J, Liang SQ, Wu WL, Su Z, Li L, Ai P, He YX, Zang J, Chen L, Lin L, Huang SH, Xu C, Lv JW, Li YQ, Hong SB, Jie YS, Li H, Huang SW, Liang YL, Wang YQ, Peng YL, Zhu JH, Zang SB, Liu SR, Lin QG, Li HJ, Tian L, Liu LZ, Zhao HY, Lin AH, Li JB, Liu N, Tang LL, Chen YP, Sun Y and Ma J. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet 2024; 403: 2720-2731.","journal-title":"Lancet"},{"key":"ref13","unstructured":"Geng ZY, Chen NX, You W, Liu K, Gu X, Wei J, Ma L and Zhang XX. Efficacy of non-surgical comprehensive treatment for locally advanced hypopharyngeal carcinoma with cervical esophagus invasion. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2023; 58: 773-780."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.1038\/s41467-024-49121-3","article-title":"Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial","volume":"15","author":"Gong","year":"2024","unstructured":"Gong H, Tian S, Ding H, Tao L, Wang L, Wang J, Wang T, Yuan X, Heng Y, Zhang M, Shi Y, Xu C, Wu C, Wang S and Zhou L. Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial. Nat Commun 2024; 15: 5251.","journal-title":"Nat Commun"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1007\/s00262-023-03557-6","article-title":"Evaluation of neoadjuvant chemotherapy combined with PD-1 inhibitors in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma: a comparative study of antitumor activity","volume":"72","author":"Xu","year":"2023","unstructured":"Xu P, Fang Q, Zhao Z, Cao F, Wu D and Liu X. Evaluation of neoadjuvant chemotherapy combined with PD-1 inhibitors in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma: a comparative study of antitumor activity. Cancer Immunol Immunother 2023; 72: 4209-4219.","journal-title":"Cancer Immunol Immunother"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1466310","DOI":"10.3389\/fimmu.2024.1466310","article-title":"Comparison of the efficacy and safety of neoadjuvant PD-1 inhibitors plus chemotherapy vs targeted therapy plus chemotherapy in locally advanced hypopharyngeal squamous cell carcinoma","volume":"15","author":"Gao","year":"2024","unstructured":"Gao W, Feng L, Zhao X, Huang Z, Chen D, Yin G, Guo W, Zhong Q, Chen X, Fang J, Zhang Y and Huang Z. Comparison of the efficacy and safety of neoadjuvant PD-1 inhibitors plus chemotherapy vs targeted therapy plus chemotherapy in locally advanced hypopharyngeal squamous cell carcinoma. Front Immunol 2024; 15: 1466310.","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Wang J, Meng Y, Zhang Y, Wu R, Gui L, Chen X, Huang X, Wang K, Qu Y, Ma Y, Luo J, Liu S and Yi J. The efficacy of PD-1 inhibitor and induction chemotherapy followed by radical radiotherapy in locally advanced head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2024; 120: e799.","DOI":"10.1016\/j.ijrobp.2024.07.1756"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Soluk-Tekkesin M and Wright JM. The world health organization classification of odontogenic lesions: a summary of the changes of the 2022 (5th) edition. Turk Patoloji Derg 2022; 38: 168-184.","DOI":"10.5146\/tjpath.2022.01573"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"1-update and clarification: from the RECIST committee","volume":"62","author":"LH","year":"2016","unstructured":"Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD and Seymour L. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer 2016; 62: 132-137.","journal-title":"Eur J Cancer"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1365-2273.2005.01022.x","article-title":"The reliability and validity of patient self-rating of their own voice quality","volume":"30","author":"Lee","year":"2005","unstructured":"Lee M, Drinnan M and Carding P. The reliability and validity of patient self-rating of their own voice quality. Clin Otolaryngol 2005; 30: 357-361.","journal-title":"Clin Otolaryngol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ijporl.2017.12.018","article-title":"Reliability and validity of the Chinese pediatric voice handicap index","volume":"105","author":"Liu","year":"2018","unstructured":"Liu K, Liu S, Zhou Z, Ren Q, Zhong J, Luo R, Qin H, Zhang S and Ge P. Reliability and validity of the Chinese pediatric voice handicap index. Int J Pediatr Otorhinolaryngol 2018; 105: 127-131.","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamasurg.2023.7996","article-title":"Total neoadjuvant therapy with PD-1 blockade for high-risk proficient mismatch repair rectal cancer","volume":"159","author":"Li","year":"2024","unstructured":"Li Y, Pan C, Gao Y, Zhang L, Ji D, Cui X, Zhang X, Cai Y, Zhang Y, Yao Y, Wang L, Leng J, Zhan T, Wu D, Gao Z, Sun YS, Li Z, Luo H and Wu A. Total neoadjuvant therapy with PD-1 blockade for high-risk proficient mismatch repair rectal cancer. JAMA Surg 2024; 159: 529-537.","journal-title":"JAMA Surg"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1110281","DOI":"10.3389\/fonc.2023.1110281","article-title":"The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma","volume":"13","author":"Xiang","year":"2023","unstructured":"Xiang X, Chen P, Lan F, Ma L, Jin J and Zhang Y. The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma. Front Oncol 2023; 13: 1110281.","journal-title":"Front Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"216167","DOI":"10.1016\/j.canlet.2023.216167","article-title":"Improvement strategy for immune checkpoint blockade: a focus on the combination with immunogenic cell death inducers","volume":"562","author":"Shi","year":"2023","unstructured":"Shi F, Huang X, Hong Z, Lu N, Huang X, Liu L, Liang T and Bai X. Improvement strategy for immune checkpoint blockade: a focus on the combination with immunogenic cell death inducers. Cancer Lett 2023; 562: 216167.","journal-title":"Cancer Lett"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1017\/S0022215123001421","article-title":"Novel techniques for prevention of post-operative pharyngocutaneous fistula in locally advanced laryngeal and hypopharyngeal cancers","volume":"138","author":"Lambor","year":"2024","unstructured":"Lambor DV, Shetgaunkar RR, Lambor S, Sa C and Vijaykumar R. Novel techniques for prevention of post-operative pharyngocutaneous fistula in locally advanced laryngeal and hypopharyngeal cancers. J Laryngol Otol 2024; 138: 345-348.","journal-title":"J Laryngol Otol"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Luo X, Huang X, Liu S, Wang X, Luo J, Xiao J, Wang K, Qu Y, Chen X, Zhang Y, Wang J, Zhang J, Xu G, Gao L, Wu R and Yi J. Response-adapted treatment following radiotherapy in patients with resectable locally advanced hypopharyngeal carcinoma. JAMA Netw Open 2022; 5: e220165.","DOI":"10.1001\/jamanetworkopen.2022.0165"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1158\/2326-6066.CIR-23-0903","article-title":"A bifunctional antibody targeting PD-1 and TGF-β signaling has antitumor activity in combination with radiotherapy and attenuates radiation-induced lung injury","volume":"13","author":"Wang","year":"2025","unstructured":"Wang S, Xu D, Wang Y, Zhou Y, Xiao L, Li F, Tu J, Qin W, Tian S, Zheng B, Wang Y, Yuan XL, Liu Y and Liu B. A bifunctional antibody targeting PD-1 and TGF-β signaling has antitumor activity in combination with radiotherapy and attenuates radiation-induced lung injury. Cancer Immunol Res 2025; 13: 767-784.","journal-title":"Cancer Immunol Res"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Gorry C, McCullagh L, O’Donnell H, Barrett S, Schmitz S, Barry M, Curtin K, Beausang E, Barry R and Coyne I. Neoadjuvant treatment for stage III and IV cutaneous melanoma. Cochrane Database Syst Rev 2023; 1: CD012974.","DOI":"10.1002\/14651858.CD012974.pub2"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s12070-020-01873-2","article-title":"Functional endoscopic evaluation of swallowing in patients treated by total laryngectomy and adjuvant treatment for advanced laryngeal and hypopharyngeal malignancies","volume":"73","author":"Harshitha","year":"2021","unstructured":"Harshitha N and Mohiyuddin SMA. Functional endoscopic evaluation of swallowing in patients treated by total laryngectomy and adjuvant treatment for advanced laryngeal and hypopharyngeal malignancies. Indian J Otolaryngol Head Neck Surg 2021; 73: 413-418.","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1001\/jamaoto.2022.2561","article-title":"Evaluation of optimal assessment schedules for surveillance after definitive locoregional treatment of locally advanced head and neck cancer: a retrospective cohort study with parametric modeling of event-free survival","volume":"148","author":"Lee","year":"2022","unstructured":"Lee HI, Lee J, Lee JH, Wu HG, Kim JH, Kim Y and Eom KY. Evaluation of optimal assessment schedules for surveillance after definitive locoregional treatment of locally advanced head and neck cancer: a retrospective cohort study with parametric modeling of event-free survival. JAMA Otolaryngol Head Neck Surg 2022; 148: 1059-1067.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1002\/hed.27119","article-title":"Induction chemotherapy of modified docetaxel, cisplatin, 5-fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma","volume":"44","author":"Li","year":"2022","unstructured":"Li R, Ye L, Zhu Y, Ding H, Wang S, Ying H, Wu C, Zhou L, Wang X and Tian S. Induction chemotherapy of modified docetaxel, cisplatin, 5-fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma. Head Neck 2022; 44: 2018-2029.","journal-title":"Head Neck"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3390\/cancers14030792","article-title":"Oral immune-related adverse events caused by immune checkpoint inhibitors: salivary gland dysfunction and mucosal diseases","volume":"14","author":"Yura","year":"2022","unstructured":"Yura Y and Hamada M. Oral immune-related adverse events caused by immune checkpoint inhibitors: salivary gland dysfunction and mucosal diseases. Cancers (Basel) 2022; 14: 792.","journal-title":"Cancers (Basel)"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2368288","DOI":"10.1080\/21645515.2024.2368288","article-title":"Induction of protective immune responses at respiratory mucosal sites","volume":"20","author":"Park","year":"2024","unstructured":"Park SC, Wiest MJ, Yan V, Wong PT and Schotsaert M. Induction of protective immune responses at respiratory mucosal sites. Hum Vaccin Immunother 2024; 20: 2368288.","journal-title":"Hum Vaccin Immunother"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1186\/s12885-022-10306-y","article-title":"Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary analysis of a randomized phase 2 trial","volume":"22","author":"Luo","year":"2022","unstructured":"Luo X, Huang X, Luo J, Xiao J, Wang K, Qu Y, Chen X, Zhang Y, Wu R, Wang J, Zhang J, Xu G, Gao L, Liu S, Wang X, He X, Luo D and Yi J. Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary analysis of a randomized phase 2 trial. BMC Cancer 2022; 22: 1235.","journal-title":"BMC Cancer"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Harker-Murray P, Mauz-Körholz C, Leblanc T, Mascarin M, Michel G, Cooper S, Beishuizen A, Leger KJ, Amoroso L, Buffardi S, Rigaud C, Hoppe BS, Lisano J, Francis S, Sacchi M, Cole PD, Drachtman RA, Kelly KM and Daw S. Nivolumab and brentuximab vedotin with or without bendamustine for R\/R Hodgkin lymphoma in children, adolescents, and young adults. Blood 2023; 141: 2075-2084.","DOI":"10.1182\/blood.2022017118"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1007\/s00405-021-07196-4","article-title":"Therapeutic strategies, oncologic and swallowing outcomes and their predictive factors in patients with locally advanced hypopharyngeal cancer","volume":"279","author":"Mattei","year":"2022","unstructured":"Mattei P, Thamphya B, Chamorey E, Scheller B, Château Y, Dassonville O, Poissonnet G, Culié D, Koulmann PH, Hechema R, Sudaka A, Saada E, Benezery K, Demard F, Elaldi R and Bozec A. Therapeutic strategies, oncologic and swallowing outcomes and their predictive factors in patients with locally advanced hypopharyngeal cancer. Eur Arch Otorhinolaryngol 2022; 279: 3629-3637.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/00016489.2024.2340086","article-title":"Laryngectomy plus postoperative radio (system) therapy versus primary radio (system) therapy for the treatment of locally advanced laryngeal and hypopharyngeal cancer - results from the university clinical cancer registry Regensburg","volume":"144","author":"Maurer","year":"2024","unstructured":"Maurer J, Kuenzel J, Bohr C, Koelbl O, Mueller K, Koller M, Concato OK, Vielsmeier V and Suess C. Laryngectomy plus postoperative radio (system) therapy versus primary radio (system) therapy for the treatment of locally advanced laryngeal and hypopharyngeal cancer - results from the university clinical cancer registry Regensburg. Acta Otolaryngol 2024; 144: 255-262.","journal-title":"Acta Otolaryngol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1158\/1078-0432.CCR-22-1128","article-title":"Inhibition of LSD1 with bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T-cell killing","volume":"28","author":"Hiatt","year":"2022","unstructured":"Hiatt JB, Sandborg H, Garrison SM, Arnold HU, Liao SY, Norton JP, Friesen TJ, Wu F, Sutherland KD, Rienhoff HY, Martins R, Houghton AM, Srivastava S and MacPherson D. Inhibition of LSD1 with bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T-cell killing. Clin Cancer Res 2022; 28: 4551-4564.","journal-title":"Clin Cancer Res"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/5\/ajcr0164074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:00:11Z","timestamp":1766023211000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/5\/ajcr0164074.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/hvrh6856","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}